These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21149483)

  • 1. The role of routine diagnostic radioiodine whole-body scintigraphy in patients with high-risk differentiated thyroid cancer.
    de Meer SG; Vriens MR; Zelissen PM; Borel Rinkes IH; de Keizer B
    J Nucl Med; 2011 Jan; 52(1):56-9. PubMed ID: 21149483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
    Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
    Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS; AlShaikh O; Tuli M; Al-Sugair A; Alamawi R; Al-Rasheed MM
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of
    Gonzalez Carvalho JM; Görlich D; Schober O; Wenning C; Riemann B; Verburg FA; Vrachimis A
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):744-756. PubMed ID: 27909769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
    Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
    Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of 495 TNM stage I or II patients with differentiated thyroid carcinoma followed up with neck ultrasonography and thyroglobulin measurements on T4 treatment.
    Pelttari H; Laitinen K; Schalin-Jäntti C; Välimäki MJ
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):323-31. PubMed ID: 18284635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer.
    Alzahrani AS; Mohamed G; Al Shammary A; Aldasouqi S; Abdal Salam S; Shoukri M
    J Endocrinol Invest; 2005 Jun; 28(6):540-6. PubMed ID: 16117196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
    Robbins RJ; Tuttle RM; Sharaf RN; Larson SM; Robbins HK; Ghossein RA; Smith A; Drucker WD
    J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
    Shammas A; Degirmenci B; Mountz JM; McCook BM; Branstetter B; Bencherif B; Joyce JM; Carty SE; Kuffner HA; Avril N
    J Nucl Med; 2007 Feb; 48(2):221-6. PubMed ID: 17268018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
    Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
    Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulated thyroglobulin and diagnostic 131-iodine whole-body scan as a predictor of distant metastasis and association with response to treatment in pediatric thyroid cancer patients.
    Garcia Alves-Junior PA; de Andrade Barreto MC; de Andrade FA; Bulzico DA; Corbo R; Vaisman F
    Endocrine; 2024 Jun; 84(3):1081-1087. PubMed ID: 38296913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
    Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
    Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of postoperative Tc-99m pertechnetate scintigraphy in estimation of remnant mass and prediction of successful ablation in patients with differentiated thyroid cancer.
    Ozdemir D; Cuhaci FN; Ozdemir E; Aydin C; Ersoy R; Turkolmez S; Cakir B
    Nucl Med Commun; 2016 Jun; 37(6):640-5. PubMed ID: 26895488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
    Danilovic DLS; Coura-Filho GB; Recchia GM; Castroneves LA; Marui S; Buchpiguel CA; Hoff AO; Kopp P
    Endocr Relat Cancer; 2022 Aug; 29(8):475-483. PubMed ID: 35613335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.